Dr.Reddy's Laboratories Ltd (REDY.BO)
|Market Cap (Mil.):||Rs457,023.00|
|Shares Outstanding (Mil.):||170.11|
* Shares in Indian drugmakers fall, with Dr Reddy's Laboratories down 1.9 percent, on concerns that sales in Russia and Ukraine will be hit given military tensions between the two countries. * Dr. Reddy's has the highest exposure to Russia and former Soviet republics, with the region comprising 14.5 percent of sales, Bank of America-Merrill Lynch says in a note dated on Monday. * Ranbaxy Laboratories Ltd and Glenmark Pharmaceuticals Ltd also have exposure to Russia and former Soviet republics,
Reuters Market Eye - Shares in Dr Reddy's Laboratories rose as much as 2.1 percent to a record high on growing hopes about its U.S. business.
Reuters Market Eye - IDFC Ltd and Dr. Reddy's Laboratories Ltd may beat July-September earnings consensus forecast when they report results later in the day, according to Thomson Reuters StarMine data.
* IDFC Ltd and Dr.Reddy's Laboratories Ltd may beat July-September earnings consensus forecast when they report results later in the day, according to Thomson Reuters StarMine data. * StarMine's SmartEstimates, which places greater emphasis on forecasts by top-rated analysts, expects IDFC to report a profit of 4.99 billion Indian rupees ($81.41 million) for the quarter, compared with a wider consensus mean estimate of 4.81 billion rupees. * Dr.Reddy's is expected to report a profit of 4.73 bil
* BSE and NSE index gain 0.5 pct each * Telecom shares surge on strong operating performance * Dr.Reddy's marks all-time high a day ahead of earnings By Abhishek Vishnoi MUMBAI, Oct 30 - India's benchmark BSE index closed at a record high on Wednesday as telecoms firms such as Bharti Airtel surged after reporting higher margins, while continued foreign inflows boosted sentiment. The BSE index has now gained 21 percent since hitting an intraday yearly low of 17,448.
Reuters Market Eye - Shares in Dr.Reddy's Laboratories up 1.2 percent after gaining 3.6 percent on Tuesday following the U.S. drug regulator's approval for selling a generic version of Celgene Corp's anti-cancer drug "Vidaza".
* Shares in India's Dr.Reddy's Laboratories up 1.2 percent after gaining 3.6 percent on Tuesday following the U.S. drug regulator's approval for selling a generic version of Celgene Corp's anti-cancer drug "Vidaza". * UBS raises Dr.Reddy's earnings estimates for FY14 and FY15 by 4 and 6 percent, respectively. It says, "First in class approvals like Vidaza and Dacogen and filing for Copaxone demonstrate Dr Reddy's strong capabilities in injectables space and focus on driving growth through nich
MUMBAI - U.S. inspectors visiting a factory in India owned by drugmaker Wockhardt Ltd in March found torn data records in a waste heap and urinals that emptied into an open drain in a bathroom six metres from the entrance to a sterile manufacturing area.